Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10754807 | 1.00 | ACE (0.39) | ACEP2RX7ALDH1A1RORCCYP3A4 | |
| SCHEMBL20077497 | 0.89 | RORC (0.35) | P2RX7ALDH1A1RORCCYP3A4CYP2C8 | |
| SCHEMBL6706546 | 0.83 | ACE (0.41) | ACEP2RX7ALDH1A1MEN1POLB | |
| SCHEMBL21432045 | 0.82 | P2RX7 (0.38) | ACEP2RX7ALDH1A1RORCCYP3A4 | |
| SCHEMBL8761596 | 0.78 | P2RX7 (0.46) | ACEP2RX7ALDH1A1MEN1POLB | |
| Hydrochloric Acid SCHEMBL8895919 | 0.77 | ACE (0.41) | ACEP2RX7ALDH1A1MEN1POLB | |
| SCHEMBL29833530 | 0.75 | MEN1 (0.57) | ACEP2RX7ALDH1A1MEN1POLB | |
| SCHEMBL8762017 | 0.75 | MEN1 (0.57) | ACEP2RX7ALDH1A1MEN1POLB | |
| SCHEMBL8613094 | 0.75 | ACE (0.40) | ACEP2RX7ALDH1A1MEN1POLB | |
| SCHEMBL24749823 | 0.74 | ACE (0.42) | ACEP2RX7ALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-10-03 | — | — | US | disclosed |
| CN-110278711-A | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | 百时美施贵宝公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-110049985-A | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | 百时美施贵宝公司 | 2019-07-23 | — | — | CN | disclosed |
| WO-2018089402-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018071620-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-19 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | ACE 3546/4885P2RX7 814/4885ALDH1A1 788/4885 |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | ACE 3546/4885P2RX7 814/4885ALDH1A1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.